Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies

NCT04354246 is registered in ClinicalTrials.gov with Compugen Ltd as lead sponsor.

NCT NCT04354246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04354246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies
Lead sponsor
Compugen Ltd
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2020
Completion date
April 1, 2026
Enrollment
94 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, colon cancer, hnscc, lung cancer, microsatellite stable colorectal carcinoma, mss-crc, multiple myeloma, ovarian cancer, plasma cell neoplasm